Breaking News Instant updates and real-time market news.

NVS

Novartis

$83.78

-0.29 (-0.34%)

05:24
08/29/18
08/29
05:24
08/29/18
05:24

Alcon announces voluntary global market withdrawal of CyPass Micro-Stent

Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The FDA approved the CyPass Micro-Stent in July 2016 for use in conjunction with cataract surgery in adult patients with mild-to-moderate primary open-angle glaucoma based on the results of the landmark two-year COMPASS study. The COMPASS study demonstrated a statistically significant reduction in intraocular pressure at two years post-surgery in subjects implanted with the CyPass Micro-Stent at the time of cataract surgery, as compared to subjects undergoing cataract surgery alone. At two years post-surgery, there was little difference in endothelial cell loss between the CyPass Micro-Stent and cataract surgery-only groups, and results were consistent with peer-review literature benchmarks of cataract-related endothelial cell loss. "We believe that withdrawing the CyPass Micro-Stent from the market is in patients' best interest and is the right thing to do," said Dr. Stephen Lane, Chief Medical Officer, Alcon. "Although we are removing the product from the market now out of an abundance of caution, we intend to partner with the FDA and other regulators to explore labeling changes that would support the reintroduction of the CyPass Micro-Stent in the future." This voluntary market withdrawal applies to all versions of the CyPass Micro-Stent. Alcon will be communicating directly with ophthalmic surgeons with recommendations for evaluating and managing those patients who have already received a CyPass Micro-Stent and instructions for returning unused devices.

  • 12

    Sep

NVS Novartis
$83.78

-0.29 (-0.34%)

08/07/18
STFL
08/07/18
INITIATION
Target $30
STFL
Buy
Alder Biopharmaceuticals initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price target, calling it an attractive, differentiated "pure play" within the migraine antiCGRP prevention market. While Matteis acknowledges it "won't be easy" for Alder to compete with Amgen (AMGN), Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), he believes the unique profile of eptinezumab remains underappreciated and may allow it to capture meaningful, above consensus share of a large, emerging drug category.
08/13/18
PIPR
08/13/18
NO CHANGE
PIPR
Overweight
Regeneron should be bought on 'largely meaningless' CRL, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends buying shares of Regeneron Pharmaceuticals on weakness after the company received a Complete Response Letter from the FDA regarding Eylea's supplemental Biologics License Application for Q12W dosing in wet macular degeneration. The CRL is "largely meaningless" as this label expansion is almost entirely a defensive move by Regeneron to counter potential Q12W labeling by competitor Novartis' (NVS) RTH258, Raymond tells investors in a research note. The analyst has "reasonable confidence" that approval for this label will come within two months. He keeps an Overweight rating on shares of Regeneron.
08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
08/23/18
MSCO
08/23/18
NO CHANGE
Target $45
MSCO
Overweight
Pfizer price target raised to $45 from $43 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Pfizer (PFE) and raised his price target to $45 based upon a 5-year CAGR for revenue growth of 3% and EPS growth of 7%. In a research note to investors, Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Additionally, he notes that political news has been "encouraging" as of late, with President Trump tweeting on July 19 "Thank you to Novartis (NVS) for not increasing your prices on prescription drugs. Likewise to Pfizer." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.

TODAY'S FREE FLY STORIES

03:25
09/25/18
09/25
03:25
09/25/18
03:25
General news
FX Action: USD-CAD has settled in the mid 1.2900s »

FX Action: USD-CAD has…

03:05
09/25/18
09/25
03:05
09/25/18
03:05
General news
FX Update: Most pairings and cross rates have posted narrow ranges »

FX Update: Most pairings…

ASPS

Altisource

$34.41

0.31 (0.91%)

02:55
09/25/18
09/25
02:55
09/25/18
02:55
Conference/Events
Altisource to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

02:10
09/25/18
09/25
02:10
09/25/18
02:10
General news
FX Action: USD-JPY posted a two-month high »

FX Action: USD-JPY posted…

01:35
09/25/18
09/25
01:35
09/25/18
01:35
General news
Asian Market Wrap: »

Asian Market Wrap:…

FDS

FactSet

$231.53

-0.05 (-0.02%)

, JBL

Jabil

$30.08

0.22 (0.74%)

20:25
09/24/18
09/24
20:25
09/24/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FDS

FactSet

$231.53

-0.05 (-0.02%)

JBL

Jabil

$30.08

0.22 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 09

    Oct

  • 13

    Nov

LOXO

Loxo Oncology

$163.07

3.91 (2.46%)

20:16
09/24/18
09/24
20:16
09/24/18
20:16
Hot Stocks
Loxo Oncology granted orphan status for solid tumors treatment »

The FDA granted Loxo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

PTLA

Portola Pharmaceuticals

$27.16

-0.39 (-1.42%)

20:15
09/24/18
09/24
20:15
09/24/18
20:15
Hot Stocks
Portola granted orphan status for cerdulatinib »

The FDA granted Portola…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Dec

TNC

Tennant

$72.75

-1.15 (-1.56%)

20:01
09/24/18
09/24
20:01
09/24/18
20:01
Hot Stocks
Tennant to Acquire Gaomei Cleaning Equipment Company, terms not stated »

Tennant Company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$73.52

-1.58 (-2.10%)

19:20
09/24/18
09/24
19:20
09/24/18
19:20
Hot Stocks
Vornado now owns 100% interest in retail condo at Marriott Marquis Times Square »

Vornado Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GOOG

Alphabet

$1,173.38

7.17 (0.61%)

, GOOGL

Alphabet Class A

$1,179.78

7.56 (0.64%)

19:08
09/24/18
09/24
19:08
09/24/18
19:08
Periodicals
Google CEO to meet with top Republican lawmakers Friday, WSJ says »

Google CEO Sundar Pichai…

GOOG

Alphabet

$1,173.38

7.17 (0.61%)

GOOGL

Alphabet Class A

$1,179.78

7.56 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

ASNA

Ascena Retail

$4.02

-0.21 (-4.96%)

, BAS

Basic Energy

$9.44

0.18 (1.94%)

18:56
09/24/18
09/24
18:56
09/24/18
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ascena…

ASNA

Ascena Retail

$4.02

-0.21 (-4.96%)

BAS

Basic Energy

$9.44

0.18 (1.94%)

KEG

Key Energy

$13.46

-0.18 (-1.32%)

PSTI

Pluristem

$1.31

(0.00%)

ARNA

Arena Pharmaceuticals

$42.80

-1.05 (-2.39%)

NOVN

Novan

$2.72

0.015 (0.56%)

SNDX

Syndax

$7.23

0.46 (6.79%)

DCPH

Deciphera

$39.80

0.78 (2.00%)

BJ

BJ's Wholesale

$28.47

-0.68 (-2.33%)

PETQ

PetIQ

$41.07

-0.55 (-1.32%)

CNP

CenterPoint Energy

$27.81

-0.23 (-0.82%)

CTL

CenturyLink

$22.90

-0.04 (-0.17%)

PBR

Petrobras

$11.40

-0.105 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 28

    Oct

  • 08

    Nov

  • 27

    Nov

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

PBR

Petrobras

$11.40

-0.105 (-0.91%)

18:54
09/24/18
09/24
18:54
09/24/18
18:54
Hot Stocks
Breaking Hot Stocks news story on Petrobras »

Petrobras reports August…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSN

VeriSign

$158.97

-0.79 (-0.49%)

18:39
09/24/18
09/24
18:39
09/24/18
18:39
Recommendations
VeriSign analyst commentary at JPMorgan »

VeriSign price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TI

Telecom Italia

$6.54

-0.1 (-1.51%)

18:35
09/24/18
09/24
18:35
09/24/18
18:35
Periodicals
Telecom Italia discussed Nextel bid at board meeting, Bloomberg says »

Telecom Italia's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSG

Inseego

$4.01

-0.08 (-1.96%)

18:31
09/24/18
09/24
18:31
09/24/18
18:31
Hot Stocks
Inseego names John Weldon to head Enterprise SaaS Solutions division »

Inseego announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$46.30

-0.48 (-1.03%)

18:31
09/24/18
09/24
18:31
09/24/18
18:31
Periodicals
PG&E says will invest $360M in electric car infrastructure, Bloomberg says »

PG&E senior manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 08

    Oct

  • 11

    Nov

KKR

KKR

$28.25

-0.01 (-0.04%)

18:21
09/24/18
09/24
18:21
09/24/18
18:21
Hot Stocks
KKR announces intra-quarter Q3 monetization activity »

KKR announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$267.35

0.6 (0.22%)

, EVHC

Envision Healthcare

$45.72

0.07 (0.15%)

18:17
09/24/18
09/24
18:17
09/24/18
18:17
Periodicals
UnitedHealth tells Hospitals about Envision ER contracts, Reuters says »

UnitedHealth (UNH) plans…

UNH

UnitedHealth

$267.35

0.6 (0.22%)

EVHC

Envision Healthcare

$45.72

0.07 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Oct

AMZN

Amazon.com

$1,934.50

16.75 (0.87%)

, UBER

Uber

$0.00

(0.00%)

18:14
09/24/18
09/24
18:14
09/24/18
18:14
Periodicals
Amazon has made two approaches to buy Deliveroo, Telegraph reports »

Amazon has made two…

AMZN

Amazon.com

$1,934.50

16.75 (0.87%)

UBER

Uber

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BK

BNY Mellon

$52.36

-0.9 (-1.69%)

17:48
09/24/18
09/24
17:48
09/24/18
17:48
Hot Stocks
BNY Mellon Investment Management to close EACM Advisors »

BNY Mellon Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

EPZM

Epizyme

$10.23

-0.075 (-0.73%)

17:44
09/24/18
09/24
17:44
09/24/18
17:44
Initiation
Epizyme initiated at Leerink »

Epizyme initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 02

    Oct

NAVB

Navidea

$0.25

-0.0135 (-5.14%)

17:31
09/24/18
09/24
17:31
09/24/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Navidea »

John K. Scott, Jr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYL

Dragon Victory

$1.46

(0.00%)

17:30
09/24/18
09/24
17:30
09/24/18
17:30
Hot Stocks
Breaking Hot Stocks news story on Dragon Victory »

White Knight Ltd reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$68.18

0.89 (1.32%)

, RDS.B

Royal Dutch Shell

$70.25

0.67 (0.96%)

17:30
09/24/18
09/24
17:30
09/24/18
17:30
Periodicals
Shell CEO weighs $30B LNG export terminal in Canada, WSJ says »

Royal Dutch Shell CEO Ben…

RDS.A

Royal Dutch Shell

$68.18

0.89 (1.32%)

RDS.B

Royal Dutch Shell

$70.25

0.67 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.